- $163.96bn
- $178.41bn
- $29.44bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 43.47 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -37.23% | ||
| Dividend Yield (f) | 2.48% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.97 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.03 | ||
| Price to Sales | 5.51 | ||
| EV to EBITDA | 13.59 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 22.16% | ||
| Return on Equity | 43.19% | ||
| Operating Margin | 34.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,416.72 | 32,320.99 | 3.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +7.16 | +33.63 | -9.35 | +23.79 | +7.3 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
Directors
- Daniel O'Day CHM (56)
- Andrew Dickinson CFO (51)
- Flavius Martin EVP
- Johanna Mercier OTH (51)
- Merdad Parsey OTH (58)
- Kevin Lofton LED (66)
- Jacqueline Barton IND (68)
- Jeffrey Bluestone IND (67)
- Sandra Horning IND (72)
- Kelly Kramer IND (53)
- Harish Manwani IND (68)
- Javier Rodriguez IND (50)
- Anthony Welters IND (66)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 22nd, 1987
- Public Since
- January 22nd, 1992
- No. of Shareholders
- 1,305
- No. of Employees
- 17,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 1,241,569,874
- Address
- 333 LAKESIDE DR, FOSTER CITY, 94404-1147
- Web
- https://www.gilead.com
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Latest News for GILD
Upcoming Events for GILD
Gilead Sciences Inc at RBC Capital Markets Global Healthcare Conference
Gilead Sciences Inc at Bernstein Strategic Decisions Conference
Gilead Sciences, Inc to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL
Gilead Sciences Inc at Goldman Sachs Healthcare Conference
Dividend For GILD34.SA - 1.4112 BRL
Dividend For GILDm.BA - 0.2050 USD
Dividend For GILD.TO - 0.1659 CAD
Dividend For GILD.OQ - 0.8200 USD
Q2 2026 Gilead Sciences Inc Earnings Release
Q3 2026 Gilead Sciences Inc Earnings Release
Similar to GILD
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals,
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 02:51 UTC, shares in Gilead Sciences, are trading at $132.06. This share price information is delayed by 15 minutes.
Shares in Gilead Sciences, last closed at $132.06 and the price had moved by +34.23% over the past 365 days. In terms of relative price strength the Gilead Sciences, share price has outperformed the S&P500 Index by +5.88% over the past year.
The overall consensus recommendation for Gilead Sciences, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Gilead Sciences, dividend yield is 2.42% based on the trailing twelve month period.
Last year, Gilead Sciences, paid a total dividend of $3.19, and it currently has a trailing dividend yield of 2.42%.Looking ahead, shares in Gilead Sciences, are due to go ex-dividend on 2026-06-15 and the next dividend pay date is 2026-06-29.
Gilead Sciences, are due to go ex-dividend on 2026-06-15 and the next dividend pay date is 2026-06-29. The historic dividend yield on Gilead Sciences, shares is currently 2.42%.
To buy shares in Gilead Sciences, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $132.06, shares in Gilead Sciences, had a market capitalisation of $163.96bn.
Here are the trading details for Gilead Sciences,:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GILD
Based on an overall assessment of its quality, value and momentum Gilead Sciences, is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Gilead Sciences, is $158.44. That is 19.98% above the last closing price of $132.06.
Analysts covering Gilead Sciences, currently have a consensus Earnings Per Share (EPS) forecast of -$0.82 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gilead Sciences,. Over the past six months, its share price has underperformed the S&P500 Index by -6.04%.
As of the last closing price of $132.06, shares in Gilead Sciences, were trading +3.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Gilead Sciences, PE ratio based on its reported earnings over the past 12 months is 43.47. The shares last closed at $132.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Gilead Sciences,'s management team is headed by:
- Daniel O'Day - CHM
- Andrew Dickinson - CFO
- Flavius Martin - EVP
- Johanna Mercier - OTH
- Merdad Parsey - OTH
- Kevin Lofton - LED
- Jacqueline Barton - IND
- Jeffrey Bluestone - IND
- Sandra Horning - IND
- Kelly Kramer - IND
- Harish Manwani - IND
- Javier Rodriguez - IND
- Anthony Welters - IND